Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-B7-1 Antibody-APC (2N313) is a APC-conjugated Rabbit antibody targeting B7-1. Anti-B7-1 Antibody-APC (2N313) can be used in FCM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 T | $81 | 7-10 days | |
| 100 T | $176 | 7-10 days |
| Description | Anti-B7-1 Antibody-APC (2N313) is a APC-conjugated Rabbit antibody targeting B7-1. Anti-B7-1 Antibody-APC (2N313) can be used in FCM. |
| Synonyms | CD80 molecule |
| Ig Type | Rabbit IgG |
| Clone | 2N313 |
| Reactivity | Mouse |
| Specificity | Mouse B7-1/CD80 |
| Verified Activity | Flow cytometric analysis of Mouse CD80 expression on LPS-stimulated BABL/c splenocytes. Cells were stained with APC-conjugated anti-Mouse CD80. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
| Application | |
| Recommended Dose | 5 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse B7-1/CD80 (rM B7-1/CD80; TMPY-02307; Q00609-1; Met1-Lys245) and conjugated with APC under optimum conditions, the unreacted APC was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Research Background | The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| Conjucates | APC |
| Others Formats | Unconjugated/FITC/PE |
| Antibody Types Available | 4 |
| Immunogen | Recombinant Protein: Mouse B7-1/CD80 Protein (TMPY-02307) |
| Antigen Species | Mouse |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| Transport | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.